periplocin and Heart-Failure

Heart failure with preserved ejection fraction (HFpEF) is a common public health problem associated with increased morbidity and long-term mortality. However, effective treatment for HFpEF was not discovered yet. In the present study, we aimed to decipher the effects of Periplocin on DOCA-induced heart failure rats and explore the possible underlying mechanisms. We demonstrated that Periplocin could significantly attenuate cardiac structural remodeling and improve cardiac diastolic function. Of note, Periplocin significantly inhibited the recruitment of inflammatory and immune cells and decreased the expression of serum inflammatory cytokines. Meanwhile, Periplocin had the effect of cardiac glycosides to improve cardiomyocyte contractility and calcium transient amplitude. These findings indicate that Periplocin might be a potential medicine to treat HFpEF in patients.

Topics: Animals; Desoxycorticosterone Acetate; Heart Failure; Myocytes, Cardiac; Rats; Stroke Volume; Ventricular Remodeling

Topics: Cardiac Glycosides; Cardiotonic Agents; Diuretics; Glycosides; Heart Failure; Humans; Saponins